A computational dynamic model of combination treatment for type II inhibitors with asciminib.

ABSTRACT: Despite continuous strides forward in drug development, resistance to treatment looms large in the battle against cancer as well as communicable diseases. Chronic myeloid leukemia (CML) is treated with targeted therapy and treatment is personalized when resistance arises. It has been extensively studied and is used as a model for targeted therapy. In this study, we examine combination treatments of type II Abl1 inhibitors and asciminib (an allosteric regulator) through a computational model at patient relevant concentrations. Due to the separate binding sites of type II inhibitors and asciminib, we propose their combination treatment as potentially robust to resistance. We find that the simultaneous cobinding of type II inhibitors and asciminib is high in synergetic combinations. As an aid

SUBMITTER: Sheehan JR 

PROVIDER: S-EPMC12268125 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature